tirzepatide surpass-4 reduces albuminuria among adults with type 2 diabetes in SURPASS trials Tirzepatide for the Maintenance of

FG reports consultancies or paid advisory board memberships for Eli Lilly, Medtronic, Novo Nordisk, Roche Diabetes Care, and Sanofi

- In SURMOUNT-1, people taking Zepbound at the highest dose (15 mg) lost on average 48 pounds, and people taking the lowest dose (5 mg) lost on average 34 pounds (compared to 7 pounds on placebo)

The three most common causes of GLP-1-related oral odor are belching, bad breath (halitosis), and ketosis, McGowan says

[3,5] The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours) [1] Storage Store in refrigerator Pens can be stored at room temperature for up to 21 days [1] LONG-TERM SAFETY Tirzepatide was FDA-approved in 2022

Supplementation beyond B6 While the compound formulation provides B6, other nutritional gaps may need attention